logo
  

Amazon, Microsoft, Pfizer To Invest Billions In French Projects

microsoftpfizeramazon may13 lt

Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said.

French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment, as part of the Government's efforts to re-industrialize the country.

In a statement, Amazon said it plans to invest more than 1.2 billion euros or $1.3 billion in its French operations, which is expected to create more than 3,000 permanent jobs in the country.

Further, tech and software giant Microsoft plans to invest 4 billion euros or $4.3 billion in France, mainly to focus on the artificial intelligence or AI sector.

Healthcare companies Pfizer and AstraZeneca also announced investments worth a total of nearly $1 billion. Other companies, including GSK and Accenture are expected to announce investments as part of the event.

GSK would announce new investments while Accenture would announce plans to set up new jobs in the artificial intelligence sector.

Morgan Stanley would open a new office in the country, its new European campus, which is expected to create 100 more jobs in Paris.

French Finance Minister Bruno Le Maire reportedly will also host meetings with the CEOs of JPMorgan, Goldman Sachs, Morgan Stanley and Bank of America, among others.

At last year's summit, around 13 billion euros worth of foreign investments were announced by the country.

Under Amazon's planned investment, Amazon Web Services is expected to increase cloud infrastructure in the Paris area to support France's generative AI opportunity, and logistics infrastructure to increase speed of delivery and reduce carbon emissions. Frederic Duval, country manager at Amazon France said the latest jobs are in addition to the 2,000 jobs the firm announced for 2024. Since 2010, Amazon has invested more than 20 billion euros in its French operations.

Microsoft's planned 4 billion euros or $4.3 billion investment in France would mainly focus on the artificial intelligence or AI sector. According to its vice chair and president Brad Smith, the company would set up a data centre in the French city of Mulhouse.

Further, drug major Pfizer would invest 500 million euros or $538.5 million in France to build up its research and development work, while AstraZeneca would invest $388 million for its site at Dunkirk.

Le Maire reportedly said, "New industries and the new economy need massive amounts of capital. We urgently need to take concrete steps to get the capital markets union going. … Europe needs money. If not, it will continue to lose out in terms of productivity to the United States and China."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft has launched a new category of Windows PCs designed for Artificial Intelligence (AI) that are slated to be the fastest and most intelligent Windows PCs ever built. The Copilot+ PCs come with built-in AI hardware and will support AI features across the operating system. Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit. While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings...

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT